ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Local efficacy and safety of CT-guided Iodine-125 seed implantation in the treatment of recurrent malignant tumors: a retrospective study.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dose control in robot-assisted seed brachytherapy: challenges, current status, and future directions.Journal of robotic surgery · 2026Review
- Multiphysics finite element analysis of vertebral stability in simulated osteolytic lumbar defects treated withFrontiers in bioengineering and biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPermanent radioactive Iodine-125 seed implantation (RISI) is a minimally invasive internal radiation technique that effectively kills tumor cells. This study aimed to investigate the local efficacy and safety of RISI in the treatment of recurrent malignant tumors and to analyze the prognostic factors.
methodsWe retrospectively evaluated 162 patients with recurrent malignant tumors who received RISI in Zhejiang Provincial People's Hospital during January 2020 to December 2022. Local control time (LCT), tumor response, particle implantation site, tumor size, needle number, particle activity, particle number, dose parameters, and adverse reactions were analyzed.
resultsWith a median follow-up of 14 months, the complete response (CR) rate was 17.9%, partial response (PR) 45.1%, stable disease (SD) 27.8%, and progressive disease (PD) 9.2% in all patients. The median LCT of patients with head and neck metastasis, chest metastasis, abdominal pelvis metastasis, and para-bone metastasis was 11.0, 11.5, 8, and 13 months, while median overall survival (OS) was 11, 11.5, 8, and 13 months, respectively. Univariate analysis showed that tumor size, postoperative D90 dose, and postoperative D100 dose were factors affecting LCT. Smaller tumor size and higher dose level at the implant site contributed to the significantly longer LCT. The dosimetry results showed that D90, D100, V100, V150, and V200 were consistent before and after the operation. In terms of adverse reactions, except for 5 patients with mild pneumothorax, no other serious adverse reactions were reported.
conclusionsThe application of CT-guided Iodine-125 implantation in the treatment of patients with advanced malignant tumors demonstrates favorable clinical efficacy, achieving a high rate of LCT while maintaining a superior level of safety and minimal postoperative adverse reactions.
Indexed as
Identifiers
41329257What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.